1. Show article details.

    Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer

    GlobeNewswire – 9:00 AM ET 09/08/2021

    XBiotech Inc.  today announced that Benjamin Musher M.D., will chair XBiotech’s clinical program for pancreatic cancer.

  2. Show article details.

    XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director

    GlobeNewswire – 9:00 AM ET 08/30/2021

    XBiotech Inc.  today announced the addition of Mark Ziats, M.D. Ph.D. as Medical Director. Dr. Ziats received his medical training in Texas from Baylor College of Medicine in Houston; received his PhD in genetics from the University of Cambridge, England as part of the NIH-Cambridge Biomedical Scholars Program; and completed his residency in Internal Medicine at the University of Michigan.

  3. Show article details.

    XBiotech Announces Payment of Dividend to Holders of Common Stock

    GlobeNewswire – 11:03 AM ET 07/30/2021

    XBiotech Inc. (XBIT) has completed payment to holders of its Common Stock of a previously announced dividend in the amount of USD$75,000,000.00. Based on the number of shares of Common Stock issued and outstanding on the record date for the dividend, each such holder received USD$2.47 per share on July 23, 2021.

  4. Show article details.

    XBiotech Announces Dividend to Holders of Common Stock

    GlobeNewswire – 4:30 PM ET 07/06/2021

    XBiotech Inc.’s Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock.

  5. Show article details.

    XBiotech Announces Receipt of $75 Million from Sale of Antibody

    GlobeNewswire – 11:46 AM ET 06/30/2021

    XBiotech (XBIT) announced today it received $75 million from funds escrowed as part of its December 2019 sale of bermekimab. XBiotech (XBIT) developed technology to clone monoclonal antibodies from the peripheral blood of humans with natural immunity against diseases. As part of the sale agreement for bermekimab, XBiotech (XBIT) agreed to continue under contract to manufacture the antibody and supply finished product.

  6. Show article details.

    XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer

    GlobeNewswire – 8:30 AM ET 06/23/2021

    XBiotech Inc. (XBIT) has enrolled the first patient in its 1-BETTER study, a randomized, double-blind, placebo-controlled clinical study to evaluate XB2001 in combination chemotherapy for treatment of Pancreatic Cancer. XBiotech’s novel anti-cancer agent, XB2001, is being assessed in combination with ONIVYDE + 5-FU/LV chemotherapy regimens.

  7. Show article details.

    French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer

    GlobeNewswire – 8:00 AM ET 05/03/2021

    XBiotech (XBIT) announced today that it had reached an agreement to supply its new cancer drug XB20-01 to INSERM, and its Federation of Digestive Oncology group, a French organization which supports world-leading innovation for treating colorectal cancer.

  8. Show article details.

    FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer

    GlobeNewswire – 4:00 AM ET 04/19/2021

    XBiotech (XBIT) announced today that the FDA has granted permission to commence clinical trials with its novel drug candidate for treating patients with pancreatic cancer. Pancreatic cancer is typically identified at an advanced stage and treatment often includes surgery and aggressive chemotherapy.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Aug
    09

    XBIT announced Q2 earnings.

  • Jul
    15

    XBIT ex-Dividend for $2.50 on 07/15/2021

    • Announce Date: 07/06/2021
    • Record Date: 07/16/2021
    • Pay Date: 07/23/2021
Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.